262 related articles for article (PubMed ID: 28289945)
1. A novel representation of inter-site tumour heterogeneity from pre-treatment computed tomography textures classifies ovarian cancers by clinical outcome.
Vargas HA; Veeraraghavan H; Micco M; Nougaret S; Lakhman Y; Meier AA; Sosa R; Soslow RA; Levine DA; Weigelt B; Aghajanian C; Hricak H; Deasy J; Snyder A; Sala E
Eur Radiol; 2017 Sep; 27(9):3991-4001. PubMed ID: 28289945
[TBL] [Abstract][Full Text] [Related]
2. Association between CT-texture-derived tumor heterogeneity, outcomes, and BRCA mutation status in patients with high-grade serous ovarian cancer.
Meier A; Veeraraghavan H; Nougaret S; Lakhman Y; Sosa R; Soslow RA; Sutton EJ; Hricak H; Sala E; Vargas HA
Abdom Radiol (NY); 2019 Jun; 44(6):2040-2047. PubMed ID: 30474722
[TBL] [Abstract][Full Text] [Related]
3. Integration of proteomics with CT-based qualitative and radiomic features in high-grade serous ovarian cancer patients: an exploratory analysis.
Beer L; Sahin H; Bateman NW; Blazic I; Vargas HA; Veeraraghavan H; Kirby J; Fevrier-Sullivan B; Freymann JB; Jaffe CC; Brenton J; Miccó M; Nougaret S; Darcy KM; Maxwell GL; Conrads TP; Huang E; Sala E
Eur Radiol; 2020 Aug; 30(8):4306-4316. PubMed ID: 32253542
[TBL] [Abstract][Full Text] [Related]
4. 19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes.
Aziz D; Etemadmoghadam D; Caldon CE; Au-Yeung G; Deng N; Hutchinson R; ; Bowtell D; Waring P
Gynecol Oncol; 2018 Nov; 151(2):327-336. PubMed ID: 30209015
[TBL] [Abstract][Full Text] [Related]
5. High cyclin E1 protein, but not gene amplification, is prognostic for basal-like breast cancer.
Aziz D; Lee C; Chin V; Fernandez KJ; Phan Z; ; ; Waring P; Caldon CE
J Pathol Clin Res; 2022 Jul; 8(4):355-370. PubMed ID: 35384378
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the 19q12 amplification including CCNE1 and URI in different epithelial ovarian cancer subtypes.
Noske A; Henricksen LA; LaFleur B; Zimmermann AK; Tubbs A; Singh S; Storz M; Fink D; Moch H
Exp Mol Pathol; 2015 Feb; 98(1):47-54. PubMed ID: 25527175
[TBL] [Abstract][Full Text] [Related]
7. Survival time prediction in patients with high-grade serous ovarian cancer based on
He D; Zhang X; Chang Z; Liu Z; Li B
BMC Cancer; 2024 Mar; 24(1):337. PubMed ID: 38475819
[TBL] [Abstract][Full Text] [Related]
8. Reduced RBX1 expression induces chromosome instability and promotes cellular transformation in high-grade serous ovarian cancer precursor cells.
Bungsy M; Palmer MCL; Jeusset LM; Neudorf NM; Lichtensztejn Z; Nachtigal MW; McManus KJ
Cancer Lett; 2021 Mar; 500():194-207. PubMed ID: 33290867
[TBL] [Abstract][Full Text] [Related]
9. CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes.
Petersen S; Wilson AJ; Hirst J; Roby KF; Fadare O; Crispens MA; Beeghly-Fadiel A; Khabele D
Gynecol Oncol; 2020 May; 157(2):405-410. PubMed ID: 32044108
[TBL] [Abstract][Full Text] [Related]
10. Biomarker Assessment of HR Deficiency, Tumor
Stronach EA; Paul J; Timms KM; Hughes E; Brown K; Neff C; Perry M; Gutin A; El-Bahrawy M; Steel JH; Liu X; Lewsley LA; Siddiqui N; Gabra H; Lanchbury JS; Brown R
Mol Cancer Res; 2018 Jul; 16(7):1103-1111. PubMed ID: 29724815
[TBL] [Abstract][Full Text] [Related]
11. Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma.
Chan AM; Enwere E; McIntyre JB; Wilson H; Nwaroh C; Wiebe N; Ou Y; Liu S; Wiedemeyer K; Rambau PF; Grevers X; Morris DG; Neri P; Gilks CB; Visser F; Le N; Luo L; Cook LS; Köbel M
J Pathol Clin Res; 2020 Oct; 6(4):252-262. PubMed ID: 32391646
[TBL] [Abstract][Full Text] [Related]
12. High-Grade Serous Ovarian Cancer: Associations between BRCA Mutation Status, CT Imaging Phenotypes, and Clinical Outcomes.
Nougaret S; Lakhman Y; Gönen M; Goldman DA; Miccò M; D'Anastasi M; Johnson SA; Juluru K; Arnold AG; Sosa RE; Soslow RA; Vargas HA; Hricak H; Kauff ND; Sala E
Radiology; 2017 Nov; 285(2):472-481. PubMed ID: 28628421
[TBL] [Abstract][Full Text] [Related]
13. Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer.
Nakayama N; Nakayama K; Shamima Y; Ishikawa M; Katagiri A; Iida K; Miyazaki K
Cancer; 2010 Jun; 116(11):2621-34. PubMed ID: 20336784
[TBL] [Abstract][Full Text] [Related]
14. Pathogenesis and heterogeneity of ovarian cancer.
Kroeger PT; Drapkin R
Curr Opin Obstet Gynecol; 2017 Feb; 29(1):26-34. PubMed ID: 27898521
[TBL] [Abstract][Full Text] [Related]
15. CCNE1 amplification and centrosome number abnormality in serous tubal intraepithelial carcinoma: further evidence supporting its role as a precursor of ovarian high-grade serous carcinoma.
Kuhn E; Wang TL; Doberstein K; Bahadirli-Talbott A; Ayhan A; Sehdev AS; Drapkin R; Kurman RJ; Shih IeM
Mod Pathol; 2016 Oct; 29(10):1254-61. PubMed ID: 27443516
[TBL] [Abstract][Full Text] [Related]
16. Reduced SKP1 and CUL1 expression underlies increases in Cyclin E1 and chromosome instability in cellular precursors of high-grade serous ovarian cancer.
Lepage CC; Palmer MCL; Farrell AC; Neudorf NM; Lichtensztejn Z; Nachtigal MW; McManus KJ
Br J Cancer; 2021 May; 124(10):1699-1710. PubMed ID: 33731859
[TBL] [Abstract][Full Text] [Related]
17. Association between morphologic CT imaging traits and prognostically relevant gene signatures in women with high-grade serous ovarian cancer: a hypothesis-generating study.
Vargas HA; Miccò M; Hong SI; Goldman DA; Dao F; Weigelt B; Soslow RA; Hricak H; Levine DA; Sala E
Radiology; 2015 Mar; 274(3):742-51. PubMed ID: 25383459
[TBL] [Abstract][Full Text] [Related]
18. Computed tomography-based texture analysis of bladder cancer: differentiating urothelial carcinoma from micropapillary carcinoma.
Fan TW; Malhi H; Varghese B; Cen S; Hwang D; Aron M; Rajarubendra N; Desai M; Duddalwar V
Abdom Radiol (NY); 2019 Jan; 44(1):201-208. PubMed ID: 30022220
[TBL] [Abstract][Full Text] [Related]
19. Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas.
Etemadmoghadam D; deFazio A; Beroukhim R; Mermel C; George J; Getz G; Tothill R; Okamoto A; Raeder MB; Harnett P; Lade S; Akslen LA; Tinker AV; Locandro B; Alsop K; Chiew YE; Traficante N; Fereday S; Johnson D; Fox S; Sellers W; Urashima M; Salvesen HB; Meyerson M; Bowtell D;
Clin Cancer Res; 2009 Feb; 15(4):1417-27. PubMed ID: 19193619
[TBL] [Abstract][Full Text] [Related]
20. Dualistic classification of high grade serous ovarian carcinoma has its root in spatial heterogeneity.
Sun T; Zhang Z; Tian L; Zheng Y; Wu L; Guo Y; Li X; Li Y; Shen H; Lai Y; Liu J; Cui H; He S; Ren Y; Yang G
J Adv Res; 2023 Jun; 48():213-225. PubMed ID: 36038111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
